Stock listing

Shanghai:688247 Sinotherapeutics, Inc. (宣泰医药) 股价

Follow Sinotherapeutics, Inc. into a list and get an email when it puts out news.

Share price · SSE:688247

¥6.94 CNY -0.48 (-6.5%)

Close on Nov 20, 2026

Past year -33.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
¥6.93 – ¥7.18 CNYNov 20, 2026
Volume
5.19M sharesNov 20, 2026
Market cap
¥3.15B CNYAt the close on Nov 20, 2026 · price × 453.3M shares outstanding
52-week range
¥6.93 – ¥11.33 CNYLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
¥53.78M CNYMedian day 5.33M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Sinotherapeutics, Inc. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · SSE:688247 · CNY, adjusted for splits

DayCloseChange%OpenHighLowVolume
¥6.94-0.48-6.5%¥7.18¥7.18¥6.935,188,820
¥7.42-0.11-1.5%¥7.56¥7.65¥7.334,006,799
¥7.53-0.22-2.8%¥7.68¥7.76¥7.515,020,162
¥7.75-0.20-2.5%¥7.86¥7.99¥7.715,775,131
¥7.95-0.27-3.3%¥8.30¥8.46¥7.818,176,937
¥8.22+0.15+1.9%¥8.15¥8.77¥8.0312,083,594
¥8.07+0.12+1.5%¥7.96¥8.07¥7.912,762,886
¥7.95+0.06+0.8%¥8.02¥8.06¥7.892,078,350
¥7.89-0.09-1.1%¥8.10¥8.12¥7.883,769,252
¥7.98-0.22-2.7%¥7.98¥8.16¥7.894,815,306
¥8.20+0.25+3.1%¥7.94¥8.20¥7.924,637,434
¥7.95+0.16+2.1%¥7.79¥7.99¥7.645,638,333
¥7.79-0.21-2.6%¥7.93¥7.98¥7.714,675,604
¥8.00+0.14+1.8%¥7.86¥8.04¥7.624,693,895
¥7.86-0.16-2.0%¥7.98¥8.40¥7.755,889,426
¥8.02-0.38-4.5%¥8.31¥8.40¥7.994,793,738
¥8.40+0.30+3.7%¥8.11¥8.48¥8.115,334,713
¥8.10-0.48-5.6%¥8.65¥8.65¥8.074,459,328
¥8.58+0.06+0.7%¥8.52¥8.64¥8.413,693,294
¥8.52+0.11+1.3%¥8.48¥8.58¥7.905,748,739
¥8.41-0.32-3.7%¥8.72¥8.78¥8.413,952,602
¥8.73-0.10-1.1%¥8.91¥9.05¥8.703,336,520
¥8.83+0.23+2.7%¥8.53¥8.92¥8.454,913,953
¥8.60-0.23-2.6%¥8.77¥9.02¥8.347,123,995
¥8.83-0.26-2.9%¥9.27¥9.49¥8.707,804,288
¥9.09-0.15-1.6%¥9.16¥9.44¥9.034,728,604
¥9.24-0.23-2.4%¥9.54¥9.54¥9.213,660,623
¥9.47-0.16-1.7%¥9.55¥9.57¥9.185,434,015
¥9.63-0.34-3.4%¥9.98¥10.04¥9.565,328,671
¥9.97+0.35+3.6%¥9.57¥9.99¥9.288,031,216
¥9.62-0.47-4.7%¥10.10¥10.17¥9.538,332,987
¥10.09+0.22+2.2%¥9.89¥10.33¥9.827,552,306
¥9.87-0.08-0.8%¥9.87¥10.25¥9.625,930,007
¥9.95+0.07+0.7%¥9.88¥10.21¥9.807,859,641
¥9.88-0.37-3.6%¥10.18¥10.32¥9.839,297,134
¥10.25+0.24+2.4%¥10.02¥10.49¥9.908,915,571
¥10.01+0.05+0.5%¥9.80¥10.16¥9.748,870,059
¥9.96+0.71+7.7%¥9.26¥9.96¥9.2610,369,551
¥9.25+0.07+0.8%¥9.25¥9.68¥9.167,037,465
¥9.18+0.41+4.7%¥8.82¥9.56¥8.728,046,566
¥8.77+0.08+0.9%¥8.69¥8.83¥8.503,534,530
¥8.69-0.15-1.7%¥8.79¥8.92¥8.663,779,854
¥8.84+0.28+3.3%¥8.55¥8.92¥8.433,104,143
¥8.56-0.34-3.8%¥8.89¥8.92¥8.475,106,003
¥8.90-0.37-4.0%¥9.17¥9.18¥8.904,021,810
¥9.27-0.12-1.3%¥9.31¥9.39¥9.143,800,352
¥9.39+0.38+4.2%¥9.02¥9.42¥8.936,483,792
¥9.01-0.10-1.1%¥9.10¥9.16¥8.973,286,347
¥9.11+0.01+0.1%¥9.25¥9.35¥9.054,044,649
¥9.10-0.13-1.4%¥9.23¥9.33¥9.072,959,928
¥9.23-0.10-1.1%¥9.33¥9.33¥9.153,617,222
¥9.33+0.16+1.7%¥9.19¥9.38¥9.135,751,044
¥9.17-0.32-3.4%¥9.39¥9.41¥9.076,437,158
¥9.49-0.29-3.0%¥9.77¥9.78¥9.466,325,415
¥9.78+0.06+0.6%¥9.72¥9.84¥9.575,137,775
¥9.72-0.20-2.0%¥9.82¥10.14¥9.666,249,619
¥9.92+0.48+5.1%¥9.26¥9.99¥9.268,043,235
¥9.44-0.32-3.3%¥9.68¥9.98¥9.348,098,724
¥9.76-0.45-4.4%¥9.86¥10.05¥9.6811,070,288
¥10.21+0.43+4.4%¥10.17¥10.60¥9.9015,596,966
Ticker
Shanghai:688247
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
Shanghai
Currency
CNY

What changed lately

Latest news

All Sinotherapeutics, Inc. news

Sinotherapeutics, Inc. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
36 in the last 12 months · 71 in all · newest Nov 13, 2026 · oldest 2024

Valuation

P/E 174× against a median of 48.1×: 8th lowest of 9 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
¥2.33B CNY
P/E
174×
EV/sales
5.9×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
2.4×
Gross margin
39.2%
Operating margin
6.8%
Net margin
4.5%
Debt to equity
0.0×
Beta
No index for this market yet

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Sinotherapeutics, Inc. Class A · SSE:688247US$472.2MUS$350.1M174×5.9×n/a2.4×4.5%0.0×n/a
Shanghai Xiao Fang Pharmaceutical Co., Ltd. Class A · SSE:603207US$481.5MUS$373.2M16.6×4.5×n/a2.8×34.9%0.0×n/a
SMS Pharmaceuticals Limited · NSE:SMSPHARMAUS$478.3MUS$478.3M43.3×4.9×22.7×5.6×11.4%0.0×n/a
Aarti Drugs Limited · NSE:AARTIDRUGSUS$477.2MUS$543.0M19.3×1.8×13.1×2.6×8.0%0.4×n/a
Zhejiang Starry Pharmaceutical Co., Ltd. Class A · SSE:603520US$464.6MUS$595.8M116×1.5×n/a1.3×1.0%0.5×n/a
Ocumension Therapeutics · HKEX:1477US$464.3MUS$428.9Mn/a3.5×n/a0.8×−19.8%0.1×n/a
Henan Taloph Pharmaceutical Stock Co. Ltd. Class A · SSE:600222US$464.3MUS$450.4M60.8×1.8×n/a1.9×3.0%0.1×n/a
Jiangsu Lianhuan Pharmaceutical Co., Ltd. Class A · SSE:600513US$462.7MUS$504.5Mn/an/an/a2.4×n/a0.4×n/a
Shandong Wohua Pharmaceutical Co., Ltd. Class A · SZSE:002107US$462.6MUS$404.6M26.0×3.4×n/a4.4×15.1%0.0×n/a
Kwality Pharmaceuticals Ltd · NSE:KPLUS$462.3MUS$465.1M52.9×7.8×31.9×12.9×14.6%0.1×n/a
Fennec Pharmaceuticals Inc. · NASDAQ:FENCUS$462.1MUS$413.5M228×6.2×108×9.4×3.1%0.0×1.22
Median of the othersUS$464.3MUS$457.8M48.1×3.5×27.3×2.7×8.0%0.1×1.22

Financials

Annual, in CNY

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020
Revenue446.6M511.6M299.9M247.6M315.5M319.2M
Cost of revenue270.5M247.5M132.3M71.2M69.0M59.0M
Gross profit176.0M264.2M167.6M176.3M246.5M260.2M
Research and development74.9M84.9M74.0M76.0M103.6M75.8M
Selling, general and administrative14.9M17.1M14.0M10.4M20.3M30.6M
Operating income61.5M127.8M52.7M67.5M120.3M131.8M
Depreciation and amortization31.9M24.8M23.3M26.4M26.9M22.1M
EBITDA93.4M152.6M75.9M94.0M147.2M154.0M
Interest expense1.41K2.55K37.8K213.5K229.7K
Income before tax53.3M142.1M66.0M97.5M149.0M142.3M
Net income47.5M127.7M61.1M92.9M134.9M123.3M
Earnings per share, basic0.100.280.130.200.330.30

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents407.1M225.8M641.8M763.1M511.7M434.2M
Short-term investments339.3M507.7M
Receivables80.0M103.5M65.9M64.3M40.4M26.4M
Inventory72.5M102.4M84.6M29.4M40.4M41.8M
Current assets934.9M976.3M952.0M953.7M618.8M545.9M
Goodwill16.2M18.4M18.4M18.4M
Total assets1.44B1.45B1.36B1.33B865.8M743.1M
Accounts payable25.9M20.7M14.5M9.16M8.01M7.16M
Current liabilities83.0M103.2M90.7M90.1M89.5M143.2M
Total liabilities146.1M180.3M151.4M155.1M160.6M180.8M
Shareholders' equity1.29B1.27B1.21B1.18B705.2M562.4M
Shares outstanding453.3M453.3M453.3M453.3M408.0M408.0M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations95.3M130.2M13.0M73.2M145.8M210.0M
Capital spending-41.6M-94.9M-39.0M-176.3M-16.0M-38.3M0
Free cash flow53.8M35.3M-26.0M-103.2M129.8M171.7M
Dividends paid-27.8M-27.9M-28.1M
Change in cash181.1M-416.0M-121.4M251.5M77.7M175.9M

Open Financials

Filings

FilingDateTypeFiled with
(688247)"SINOTHERAPEUTICS INC."Announcement on Voluntary Disclosure of Obtaining the INVIMA Approval Number for Posaconazole Enteric-coated Tablets in ColombiaNov 13, 2026Operations updateShanghai Stock Exchange
(688247)"SINOTHERAPEUTICS INC."Report for Q3 2026Oct 29, 2026Quarterly reportShanghai Stock Exchange
(688247)"SINOTHERAPEUTICS INC."Announcement on Attending the Q3 2026 Collective Performance Briefing of Listed Companies in Shanghai JurisdictionOct 29, 2026ResultsShanghai Stock Exchange
(688247)"SINOTHERAPEUTICS INC."Announcement on Release of Pledge of Certain Shares Held by ShareholderOct 20, 2026Other filingsShanghai Stock Exchange
(688247)"SINOTHERAPEUTICS INC."Announcement on Implementation of Dividend Distribution for the First Half of 2026Oct 17, 2026DividendShanghai Stock Exchange
(688247)"SINOTHERAPEUTICS INC."Announcement on Completion of Transfer of Certain Shares under Gratuitous Donation by ShareholderOct 16, 2026Other filingsShanghai Stock Exchange
"SINOTHERAPEUTICS INC."Announcement on Change of Signing Certified Public AccountantSep 10, 2026Management or board changeShanghai Stock Exchange
"SINOTHERAPEUTICS INC."Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026Aug 27, 2026Other filingsShanghai Stock Exchange
"SINOTHERAPEUTICS INC."Announcement on Using Certain Idle Raised Funds for Cash ManagementAug 4, 2026Other filingsShanghai Stock Exchange
"SINOTHERAPEUTICS INC."Announcement on Voluntary Disclosure of Proposed Selection in the National Centralized Drug ProcurementAug 3, 2026Other filingsShanghai Stock Exchange
All 71 filings
FilingDateTypeFiled with
"SINOTHERAPEUTICS INC."Announcement on Voluntary Disclosure of Approval of Posaconazole Enteric-coated Tablets via the EU Decentralised Procedure (DCP)Jul 24, 2026Operations updateShanghai Stock Exchange
"SINOTHERAPEUTICS INC."Announcement on Voluntary Disclosure of Doxofylline Tablets Passing the Consistency Evaluation of Generic Drugs and the Addition of a New SpecificationJul 13, 2026Operations updateShanghai Stock Exchange
"SINOTHERAPEUTICS INC."Announcement on Abnormal Fluctuations in Stock TradingJul 2, 2026Other filingsShanghai Stock Exchange
Announcement on Implementation of Dividend Distribution for 2025Jun 21, 2026DividendShanghai Stock Exchange
Announcement on the Expiry of Planned Time for Shareholders with Over 5% Shares to Reduce Shares and Results of Shareholding ReductionJun 10, 2026ResultsShanghai Stock Exchange
Senior Management Member" -- Announcement on Completing Term Change and Election of the Board of Directors and Appointing Senior Management Members and Securities Affairs Representative, as well as Departure of Core Technical PersonnelMay 28, 2026Management or board changeShanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining the Colombian INVIMA Approval for Bupropion Hydrochloride Extended-release TabletsMay 25, 2026Operations updateShanghai Stock Exchange
Notice on Convening the 2025 Annual General MeetingApr 29, 2026Meeting noticeShanghai Stock Exchange
Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood ConferenceApr 28, 2026Meeting noticeShanghai Stock Exchange
Indicative Announcement on Equity Change of Shareholder with Over 5% Shares Reaching an Integral Multiple of 1% and 5% ScaleApr 14, 2026Ownership change noticeShanghai Stock Exchange
Announcement on Resolutions of the 25th Meeting of the 2nd Board of DirectorsApr 1, 2026Meeting outcomeShanghai Stock Exchange
Publicity Explanation and Verification Opinions of the Remuneration and Appraisal Committee of the Board of Directors on List of Initially Granted Incentive Objects in the 2025 Restricted Stock Incentive PlanMar 26, 2026Other filingsShanghai Stock Exchange
Announcement on Voluntary Disclosure of Sinotherapeutics® Tomato Red Grape Seed Extract Tablets Obtaining the Domestic Health Food Registration CertificateMar 17, 2026Other filingsShanghai Stock Exchange
Notice on Convening the 1st Extraordinary General Meeting in 2026Mar 16, 2026Meeting noticeShanghai Stock Exchange
Announcement on Voluntary Disclosure of Clinical Trial Applications for Collaborative Product Enzalutamide Tablets Approved by China NMPAMar 13, 2026Operations updateShanghai Stock Exchange
Announcement on Approval by Shanghai Municipal State-owned Assets Supervision and Administration Commission for Abstract of 2025 Restricted Stock Incentive Plan (Revised Draft)Mar 10, 2026Other filingsShanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining US FDA Approval Number for the Company’s Vitamin K1 TabletsMar 2, 2026Operations updateShanghai Stock Exchange
Announcement on Preliminary Earnings Estimate for 2025Feb 27, 2026ResultsShanghai Stock Exchange
Announcement on Voluntary Disclosure of the Proposed Selection of Products in the National Continuation Drug ProcurementFeb 10, 2026Operations updateShanghai Stock Exchange
Announcement on Shareholding Reduction Plan for Shareholders with Over 5% SharesFeb 9, 2026Other filingsShanghai Stock Exchange
Announcement on Provision for Asset Impairment for 2025Jan 29, 2026ResultsShanghai Stock Exchange
Summary Announcement on 2025 Restricted Stock Incentive Plan (Revised Draft)Jan 14, 2026Other filingsShanghai Stock Exchange
Announcement on Voluntary Disclosure of Clinical Trial Applications for Eisaiconazole Sulfate for Injection Approved by China NMPAJan 6, 2026Other filingsShanghai Stock Exchange
Announcement on Appointment of Senior Management MembersDec 25, 2025Management or board changeShanghai Stock Exchange
Announcement on Postponement of Investment Projects Financed by Raised FundsDec 12, 2025Operations updateShanghai Stock Exchange
Announcement on Voluntary Disclosure of the Renewal and Inclusion of the Company’s Product in the National Medical Insurance CatalogDec 8, 2025Other filingsShanghai Stock Exchange
Announcement on Attending Three-Quarter Report Collective Performance Briefing of Listed Companies in Shanghai Jurisdiction in 2025Nov 4, 2025Meeting noticeShanghai Stock Exchange
Report for Q3 2025Oct 30, 2025Quarterly reportShanghai Stock Exchange
Announcement on Voluntary Disclosure of the Proposed Selection of Products in the National Centralized Drug ProcurementOct 29, 2025Other filingsShanghai Stock Exchange
Indicative Announcement on Equity Change of Shareholding Reduction by Shareholder with Over 5% Shares to Less than 5%Oct 22, 2025Other filingsShanghai Stock Exchange
Announcement on Changing Signatory Certified Public AccountantOct 21, 2025Management or board changeShanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining US FDA Approval Number for the Company’s Sitagliptin and Metformin Hydrochloride Sustained-release TabletsOct 20, 2025Other filingsShanghai Stock Exchange
Announcement on Release of Pledge of Partial Shares Held by Shareholders with Over 5% SharesOct 16, 2025Other filingsShanghai Stock Exchange
Announcement on Implementation of Semi-annual Dividend Distribution for 2025Oct 14, 2025DividendShanghai Stock Exchange
Announcement on Pledge of Partial Shares by Shareholders with Over 5% of SharesOct 10, 2025Other filingsShanghai Stock Exchange
Announcement on Increasing Estimated Amount of Daily Related Party Transactions in 2025Sep 30, 2025Other filingsShanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining Marketing Approval by the National Medical Products Administration for the New Strength of Sitagliptin and Metformin Hydrochloride Sustained-release TabletsSep 26, 2025Operations updateShanghai Stock Exchange
Announcement on Cancellation of Some Accounts for Raised FundsSep 23, 2025Other filingsShanghai Stock Exchange
Announcement on Attending Semi-annual Collective Performance Briefing for Enterprises in Biological Products and CXO Industries on SSE STAR Market 2025Sep 5, 2025Other filingsShanghai Stock Exchange
Special Report on Semi-annual Deposit and Use of Raised Funds in 2025Aug 22, 2025Other filingsShanghai Stock Exchange
Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public OfferingAug 17, 2025Other filingsShanghai Stock Exchange
Announcement on Using Partial Idle Raised Funds for Cash ManagementAug 8, 2025Other filingsShanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining EU GMP Certification by the Wholly-owned SubsidiaryJul 17, 2025Other filingsShanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining US FDA Approval Number for the Company's Enzalutamide TabletsJun 26, 2025Other filingsShanghai Stock Exchange
Announcement on Implementation of Dividend Distribution for 2024Jun 22, 2025DividendShanghai Stock Exchange
Announcement on Resolution of the 2024 Annual General MeetingMay 29, 2025Meeting noticeShanghai Stock Exchange
Announcement on the Change of Investor HotlineMay 20, 2025Other filingsShanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining US FDA Approval Number for the Company's Dapagliflozin and Metformin Hydrochloride Sustained-release TabletsMay 12, 2025Other filingsShanghai Stock Exchange
Announcement on Changes in Some Directors, Senior Management Members, Financial Chief and Core Technical PersonnelMay 5, 2025Other filingsShanghai Stock Exchange
Announcement on Canceling the Board of Supervisors and Amending the Articles of Association and Some Management SystemsApr 29, 2025Other filingsShanghai Stock Exchange
Announcement on Pledge Release of Some Shares Held by Shareholders with Over 5% SharesMar 24, 2025Other filingsShanghai Stock Exchange
Announcement on Expiration of Plan of Shareholding Reduction by Shareholder with Over 5% Shares and Results of Shareholding ReductionMar 18, 2025Other filingsShanghai Stock Exchange
Indicative Announcement on Equity Change of Shareholders with Over 5% Shares Reaching 1%Mar 14, 2025Other filingsShanghai Stock Exchange
Announcement on Preliminary Earnings Estimate for 2024Feb 26, 2025Other filingsShanghai Stock Exchange
Announcement on the Estimated Routine Related Party Transactions for 2025Feb 19, 2025Other filingsShanghai Stock Exchange
Announcement on Implementation Results of Shares RepurchaseFeb 18, 2025Other filingsShanghai Stock Exchange
Announcement on Progress in Repurchasing SharesFeb 5, 2025Other filingsShanghai Stock Exchange
Annual Earnings Preannouncement for 2024Jan 22, 2025Other filingsShanghai Stock Exchange
Announcement on Voluntary Disclosure of the Results of the Company's Products Participating in Centralized Volume-based Procurement of Drugs Organized by the StateDec 13, 2024Other filingsShanghai Stock Exchange
Announcement on Plan of Shareholding Reduction by Shareholders with over 5% SharesNov 27, 2024Other filingsShanghai Stock Exchange
Announcement on Convening the Q3 2024 Performance BriefingNov 25, 2024Other filingsShanghai Stock Exchange

Open Filings

Cap table

Built by 6ix from Sinotherapeutics, Inc. Class A’s releases

Common shares
453,340,000
Fully diluted
453,340,000

Fully diluted

LineShares
Common shares453,340,000

Share count over time

CountShares
Nov 22, 2026453,340,000

Open Cap table

Shareholders

HolderSharesValueAs of
Siit World Equity Ex-Us Fund139KUS$174KMay 31, 2026

Open Shareholders

Log in to ask 6ix AI your own questions about Sinotherapeutics, Inc.